Table 3.

Neonatal neurodevelopmental outcomes following escalating doses HFA-BDP^a

Dose	Total Number Assessed	Cerebral palsy, n (%)	Normal or mild cognitive impairment, n (%)	Severe cognitive impairment, n (%)
200 μg bid (n = 11)	10	1/10 (10)	9 (90)	1 (10)
400 μg bid (n = 11)	10	1/10 (10)	9 (90)	1 (10)
600 μg bid (n = 10)	9	0/9 (0)	9 (100)	0 (0)
800 μg bid (n = 9)	8	1/8 (12.5)	6 (75)	2 (25)

^aHFA-BDP Hydrofluoralkane beclomethasone dipropionate, bid twice a day, μg microgram, n number, % percentage